B

Bicara Therapeutics Inc
NASDAQ:BCAX

Watchlist Manager
Bicara Therapeutics Inc
NASDAQ:BCAX
Watchlist
Price: 18.36 USD -0.65%
Market Cap: 1B USD

Relative Value

There is not enough data to reliably calculate the relative value of BCAX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BCAX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-7.8
Industry
23.7
Forward
-7.1
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8.4
Industry
22
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8.4
Industry
23.8
vs History
11
vs Industry
Median 3Y
1.8
Median 5Y
1.8
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.2
Industry
6.4
Forward
-4.6
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.2
Industry
7
Forward
-4.6
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-5.3
Industry
8.3
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-5.3
Industry
6.5
vs History
64
vs Industry
Median 3Y
12.5
Median 5Y
12.5
Industry
5.7

Multiples Across Competitors

BCAX Competitors Multiples
Bicara Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Bicara Therapeutics Inc
NASDAQ:BCAX
1B USD 0 -8.3 -5.1 -5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 738 486.8 -160 354 -194 720.9 -192 498.9
US
Abbvie Inc
NYSE:ABBV
395.1B USD 6.6 168.3 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
174.1B USD 4.8 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
148.5B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD 9.8 31.4 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 088.1 -532.8 -580.2 -564.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD 5.5 17 16.1 18.3
AU
CSL Ltd
ASX:CSL
85.8B AUD 3.7 19 12.8 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD 16.3 1 204.2 158.2 191.8
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.5 34 58.7 60.3
P/S Multiple
Revenue Growth P/S to Growth
US
B
Bicara Therapeutics Inc
NASDAQ:BCAX
Average P/S: 3 374 064.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 738 486.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 088.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
NL
argenx SE
XBRU:ARGX
14.5
49%
0.3
P/E Multiple
Earnings Growth PEG
US
B
Bicara Therapeutics Inc
NASDAQ:BCAX
Average P/E: 189.6
Negative Multiple: -8.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 354 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.3
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
9%
1.9
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 204.2
N/A N/A
NL
argenx SE
XBRU:ARGX
34
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
B
Bicara Therapeutics Inc
NASDAQ:BCAX
Average EV/EBITDA: 39.4
Negative Multiple: -5.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158.2
N/A N/A
NL
argenx SE
XBRU:ARGX
58.7
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
B
Bicara Therapeutics Inc
NASDAQ:BCAX
Average EV/EBIT: 45.5
Negative Multiple: -5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.8
N/A N/A
NL
argenx SE
XBRU:ARGX
60.3
N/A N/A